Industry Partner News: Wave Life Sciences Initiates Clinical Trial for Lead Program in Duchenne Muscular Dystrophy (DMD)

Wave Life Sciences.png

Yesterday morning, Wave Life Sciences announced the initiation of their first clinical trial in Duchenne to study their investigational therapy targeted for exon 51 skipping. For more information on Wave Life Sciences exon skipping program in Duchenne, please see the press release and letter to the patient community.